{"id":"r2-lenalidomide-plus-placebo-maintenance","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Venous thromboembolism"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lenalidomide binds to cereblon (CRBN), a component of an E3 ubiquitin ligase complex, leading to selective degradation of IKZF1 and IKZF3 proteins. This results in enhanced immune cell activation and anti-tumor effects. In this R2 regimen (lenalidomide maintenance following induction therapy), the drug is used to sustain remission and delay disease progression.","oneSentence":"Lenalidomide is an immunomodulatory agent that enhances T-cell proliferation and NK cell activity while inhibiting TNF-α and IL-6 production, combined with placebo for maintenance therapy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:08.211Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma maintenance therapy (post-induction treatment)"}]},"trialDetails":[{"nctId":"NCT04224493","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.","status":"RECRUITING","sponsor":"Epizyme, Inc.","startDate":"2020-06-11","conditions":"Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma","enrollment":612},{"nctId":"NCT03720041","phase":"PHASE3","title":"Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma","status":"UNKNOWN","sponsor":"University of Leeds","startDate":"2020-08-04","conditions":"Multiple Myeloma","enrollment":740}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Revlimid"],"phase":"phase_3","status":"active","brandName":"R2: Lenalidomide plus placebo maintenance","genericName":"R2: Lenalidomide plus placebo maintenance","companyName":"University of Leeds","companyId":"university-of-leeds","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lenalidomide is an immunomodulatory agent that enhances T-cell proliferation and NK cell activity while inhibiting TNF-α and IL-6 production, combined with placebo for maintenance therapy. Used for Multiple myeloma maintenance therapy (post-induction treatment).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}